Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-07-13 16:27:09 ET · period of report 2026-07-09 · accession 0001504783-26-000017 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-13 16:27 | 2026-07-09 | NBIX | Lippoldt Darin | CLO | M - OptEx | $81.49 | +10.0K | 64.7K | +18% | +$814.9K |
| DT | 2026-07-13 16:27 | 2026-07-09 | NBIX | Lippoldt Darin | CLO | S - Sale+OE | $179.60 | -10.0K | 54.7K | -15% | -$1.80M |
| DT | 2026-07-13 16:27 | 2026-07-09 | NBIX | Lippoldt Darin | CLO | M - OptEx | $0.00 | -10.0K | 4,965 | -67% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-09 | M | A | 10,000 | $81.49 | 64,729 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-09 | S | D | 10,000 | $179.60 | 54,729 | D | — | — | (F1) The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $179.50 to $179.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Derivative | Non-Qualified Stock Option | 2026-07-09 | M | D | 10,000 | $0.00 | 4,965 | D | $81.49 · — to 2028-02-05 | 10,000 Common Stock | (F3) The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018. |